Form 4: Lumos Pharma Executive Raffin Thomas A. Disposes of Stock Options in Merger
Merger Filing
Lumos Pharma executive Raffin Thomas A. disposed of stock options as part of a merger agreement with Double Point Ventures LLC.
Summary
- Lumos Pharma executive Raffin Thomas A. disposed of various stock options on December 12, 2024, as part of a merger agreement.
- The merger agreement, dated October 22, 2024, involved Lumos Pharma, DPV Parent, Inc., DPV MergerSub, Inc., and Double Point Ventures LLC (DPV).
- The options were disposed of in exchange for $4.25 in cash per share and one contingent value right (CVR) per share.
- In-the-money options were cancelled and exchanged for cash equal to the difference between the cash amount and the exercise price, plus one CVR per share.
- Out-of-money options were cancelled without any cash payment or CVR issuance.
Sentiment
Score: 7
Explanation: The document describes a standard merger transaction with no indication of negative or positive sentiment. The disposal of stock options is a procedural step in the merger process.
Future Outlook
The merger agreement has been executed, and the stock options have been disposed of as per the terms of the agreement.
Industry Context
This announcement reflects a merger and acquisition activity in the pharmaceutical industry, where companies are often acquired to consolidate resources and intellectual property.
Comparison to Industry Standards
- Mergers and acquisitions are common in the pharmaceutical industry, with deal structures often including cash and contingent value rights.
- The cash component of $4.25 per share is a specific valuation for Lumos Pharma in this transaction.
- Contingent value rights are often used in biotech mergers to account for future milestones or product development success, similar to other deals in the sector.
Stakeholder Impact
- Shareholders received $4.25 per share in cash and one contingent value right (CVR) per share.
- Option holders received cash for in-the-money options and CVRs, while out-of-money options were cancelled without payment.
Key Dates
| Date | Description |
|---|---|
| 2024-10-22 | Date of the Merger Agreement between Lumos Pharma, DPV Parent, Inc., DPV MergerSub, Inc., and Double Point Ventures LLC. |
| 2024-12-12 | Date of stock option disposal by Raffin Thomas A. |
| 2024-12-13 | Date of filing by attorney-in-fact Ryan Trytten. |
| 2026-07-31 | Expiration date of one of the stock options. |
| 2029-05-09 | Expiration date of one of the stock options. |
| 2030-04-02 | Expiration date of one of the stock options. |
| 2031-05-19 | Expiration date of one of the stock options. |
| 2032-05-04 | Expiration date of one of the stock options. |
| 2033-05-09 | Expiration date of one of the stock options. |
| 2034-06-04 | Expiration date of one of the stock options. |
Keywords
merger, stock options, contingent value right, Lumos Pharma, Double Point Ventures, DPV, acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.